Information for Authors drugs, pharmacology, pharmacokinetics, pharmacodynamics and drug metabolism,...

66

Information for Authors / J. Chin. Pharm. Sci. 2020, 29 (1), 66–75 http://www.jcps.ac.cn

Information for Authors

1. Scope of the Journal of Chinese Pharmaceutical Sciences Journal of Chinese Pharmaceutical Sciences (JCPS) is a peer-reviewed journal, published monthly and founded in 1992. It is

directed by Chinese Association for Science and Technology, sponsored by Chinese Pharmaceutical Association (CPA), and

undertaken by School of Pharmaceutical Sciences, Peking University. JCPS covers all areas of pharmaceutical researches, including

medicinal chemistry, pharmacognosy, natural products, pharmaceutical analysis, pharmaceutics and drug delivery, biotechnology

drugs, pharmacology, pharmacokinetics, pharmacodynamics and drug metabolism, pharmacogenomics and clinical pharmacy. It is the

interest of this journal to introduce the latest developments in pharmaceutical sciences to its readers. It is indexed as the Core Journal in

Chinese science and technology field. The journal has been included by Chemical Abstracts (CA), UIPD, Index of Copurnicus (IC),

CABI, SCOPUS, JSTChina, COAJ, EBSCO, Chinese Science Citation Database (CSCD) and the Chinese National Knowledge

Infrastructure (CNKI). In 2013–2015, JCPS got financial support from “the International Influence of Chinese Science and Technology

Journals Promotion Plan”. In 2012, 2014 and 2015, JCPS was awarded as “International Influence Outstanding Academic Journals”.

2. Types of manuscripts

Journal of Chinese Pharmaceutical Sciences publishes original research articles, reviews, perspectives and short communications.

Only manuscripts that contain original research and solid data and that are written concisely and clearly will be considered

for publication. Submitted manuscripts should not be under consideration for publication elsewhere.

Articles There are full research papers describing original and innovative results of high quality and up to date investigations.

Short communications There are significant and novel findings warrant quick communication.

Reviews There are critical summaries that highlight the past researches and describe the future trends of a pharmaceutical field.

3. Manuscript submission

JCPS recommends that authors adopt the Uniform Requirements for Manuscripts Submitted to Biomedical Journals from the

International Commitee of Medical Journal Editors (ICMJE). Further information can be found at http://www.icmje.org.

3.1. Manuscript should be submitted by e-mail at [email protected] as a word file. It also can be submitted by Scholarone

Submission System at http://www.jcps.ac.cn. If the work is supported by program funds or national key projects, please provide

the project number in the footnotes at the title page. The handling charge for each manuscript is RMB 100 yuan. If published, the

page charge is 200 yuan per page. When you send your manuscript, please pay the fee by way of postal remittance. The address of

the editorial office is: Editorial Office of Journal of Chinese Pharmaceutical Sciences, School of Pharmaceutical Sciences, Peking

University, 38 Xueyuan Road, Haidian District, Beijing 100191, China. Telephone: +86-010-82801713; +86-010-82805496.

3.2. Manuscript should include title, author and affiliation, abstract in English and Chinese, keywords, main text, figures,

tables, acknowledgments, references, graphical abstracts. Footnotes should appear at the bottom of the appropriate page. Authors

should consult a sample manuscript at the website: http://www.jcps.ac.cn.

3.3. After receiving a manuscript, a manuscript code number and copyright transfer agreement will be assigned and sent to the

corresponding author through “return receipt” or by e-mail. The author will be noticed on the decision (revision or rejection) about

2 months later. The author should revise the manuscript according to the reviewers’ comments and return the original manuscript, the

revised manuscript and a list of changes or a rebuttal against each point raised by the reviewers within 1 months. After this period,

the unreturned manuscript will be considered withdrawn and any resubmission will be treated as a new submission. The authors

should provide a final manuscript after passing the review process for the editing of the English writing by our English editors.

3.4. Before publishing, one set of page proofs in PDF format for proofreading along with the page charge notice will be

sent to the author by e-mail or by post. Please use this proof only to check the typesetting, typographical errors, completeness

and correctness of the text, tables and figures only. No significant changes to the article are allowed at this stage. To facilitate the

timely and accurate publication of your manuscript, it is important to have all your corrections sent back to us together in one

communication. Please check carefully before returning the page proofs, and all corrections, revisions, and additions must be

made directly on the proofs. Proofreading of the page proofs is solely the author’s responsibility. Revised proofs and page charges

should be returned to the editorial office within 2 d. According to guidelines of Copyright Law, editor has the right to make

changes to the manuscript.

67


3.5. After the paper is published, authors will be paid and presented with two copies of the current issue and a PDF file at no

cost. The fee for copyright and payment for the article will be paid one-time. If you do not agree, please state clearly when the

manuscript is submitted.

4. Manuscript preparation

4.1. Title

The title should reflect the content of the manuscript. It should be concise, accurate and specific. Only the first letter of the

title should be capitalized, except for proper nouns.

4.2. Authors and affiliations

Authors should be the researchers who have participated in the research work, and they are responsible for the content of the

full paper. Authors also should respond the questions and comments raised by the editors. The author names should be separated

by comma and the corresponding author should be marked with an asterisk. The detailed contact information (phone, fax and

e-mail) should be listed and the corresponding author is responsible for the communication with editors. Evincive letter of

affiliation should be provided when the copyright is changed. First letters of author names should be capitalized (e.g. Limei Zhang,

Ping Wang). The names of foreign authors should follow international tradition. The different affiliations of the authors should be

indicated by a superscript number after the author names.

4.3. Footnotes

The financial support and the contact information of the corresponding author (telephone, fax and e-mail) should be presented

in footnotes.

4.4. Abstract

The abstract should be a short paragraph that briefly describes the key contents of the full paper, not necessarily giving the remark

and explanation at the level of detail found in Chemical Abstracts. It should be understood independently of the main body of the paper.

4.5. Graphical abstract

Authors should supply a graphical abstract when the paper is accepted. The graphical abstract is used to summarize the major

point of article in a concise and pictorial form. It does not need to cover all contents of the paper. If necessary, authors may also

provide a text abstract and the text only graphic abstract may not exceed 50 words. Please see the following examples.

pp 88–99 Xiao-Xu-Ming decoction extract alleviates LPS-induced neuroinflammation associated with

down-regulating TLR4/MyD88 signaling pathway in vitro and in vivo

Xiao Cheng#, Huan Yang#, Yinglin Yang, Weihan Li, Man Liu, Yuehua Wang*, Guanhua Du*

Xiao-Xu-Ming decoction

Extract (XXM)

BV2 cells were pre-treated with XXM for 1 h and then exposed to 200 ng/mL LPS for another 24 h.

Balb/C mice were pre-treated with XXM for 7 days and then 5 mg/kg LPS-treated for 6 h.

XXM treatment

In vitro In vivo

TLR4/MyD88 signaling pathway

Neuroinflammation

(–)

(–)

68


pp 595–604 Synthetic studies toward resveratrol-based natural products polynapstilbenes A and B

Baiyang Jiang, Lingqi Qiu, Jinrong liu, Hanxuan Wang, Suwei Dong*

pp 716–727 Compound C17 inhibits the lung metastasis of breast cancer

Yaoyao Feng, Peili Jiao, Xiaoxue Yan, Zixi Xue, Ye Yao, Liang Yang, Daming Kong, Hong Su, Ling Yong,

Guoshu Chen*, Tianyan Zhou*

pp 749–759 Membrane binding of the pH sensitive antimicrobial peptide LAH4 studied by EPR spectroscopy

Yina Sheng, Shenlin Wang, Guoquan Liu*

(C17)

O

ON

N

NH2

HN

N

N

O

Fast

Fast

H+

OH–

Fast

Slow

PC

PG Very slow

O

Me

Me

O

OH

HO

HO

OOGlc

GlcPolynapstilbene

HO

Me

CH3

O

OH

OH

OMe

OMe

OH

MeO OMe

+

O

Me

Me

O

OH

MeO

HO

OH

MeO

2 steps

28%

69


4.6. Keywords

Please provide 3–10 words or phrases as keywords, which are separated with comma. The keywords should represent the core

content of the paper. General words and expressions should be avoided. First letters of all keywords should be capitalized.

4.7. The main body

A full research paper is generally consisting of three parts: introduction, experiment (materials and methods), and results and

discussion. The three sections are separated clearly with a title of each section typed in the left of a line. Subtitles under each

section are often used, which are placed at the left side of a separate line. Under each subtitle, further division can also be used

with a title typed at the left of a line followed directly by a space and the text.

4.7.1. Introduction

The introduction should concisely summarize the background of the research, raise the specific scientific questions the

research is intended to solve, and describe the basic theory, research method, and experimental design. It should clearly state the

purpose of the paper, especially the significance and novelty of the research.

4.7.2. Experimental

Because of the diversity of research this journal publishes and the great variations of the experimental methods, the organization

structure of this part can be different for different areas of research. Typically, this part should contain the general design, detailed

experimental method, data collection, data processing and statistical analysis.

4.7.2.1. Materials

The resource, species and specification of the major materials should be provided. The names of drugs should be adopted

following the guidelines of International Nonproprietary Names (INN) based on Chinese Approved Drug Names. The new drugs

approved by the state food and drug administration should use their adopted names. The code names and brand names should not

be used or rarely used. When a drug is described for the first time, the full English name should be used followed by its dose.

4.7.2.2. Research objects (animals, plants and microorganism)

For plants and medicinal herbs, the authors should give the scientific name (in italic) and indicate who identified the material

and the location of the plant specimen. For animal study, the level of sanitation and the certification number should be indicated.

Rats and mice should be hosted at the second level of sanitation at least. The genders, ages and weights of the animals or humans

should be provided. Authors are advised to follow proper guidelines when animals or humans are used as research objects.

Studies with human subjects can only be carried out after it is approved by the local ethnics committee of the responsible

organization or it follows the rules stated in the Declaration of Helsinki of 1975 (revised in 2000). The patient names and

their identification numbers in the hospital should be omitted.

4.7.2.3. Methods

The description of the research method should be as concise as possible. The significant number and the precision of the

measured data should be consistent with the methods used. For a previously reported method, a reference citation is generally

sufficient. For a modified method or a newly developed method, enough details should be provided to enable others to repeat the

procedures. The data calculation process, software and the version, and the computer program used for theoretical calculation

should be described.

4.7.2.4. Units of measurement and symbols of calculation

The units of measurement and symbols of calculation must follow the Chinese Calculation Unit Law (shortened for Calculation

Unit Law) based on the international unit system. Please also refer to Quantity and Unit (Beijing, China Standard Press). Standard

abbreviations can be used throughout the manuscript. Non-standard abbreviations must be defined in the text when it is first used.

4.7.2.5. Numbers

Numbers are generally expressed by the Arabic number system. The numbers between 0.1–1000 can be written as is and

scientific notation system is encouraged for more complicated numbers. Increase can be expressed in fold and decrease can be

expressed in percentage. When describing a range of numbers, the use of the full number is preferred, for example 2×104–6×104

or (2–6)×104 (not 2–6×104); 2%–6% (not 2–6%); 2 mm×3 mm×4 mm (not 2×3×4 mm).

The measured data should be consistent with the accuracy of the measuring instrument. Any error is only allowed at the last

digit of the number. And the correction and revision of the significant numbers should be done in one time.

4.7.2.6. Tables and figures

Tables and figures should be designed reasonably. They should be understood without reference to the text. Tables and figures

must be cited in the text and numbered sequentially in the order of appearance with Arabic numbers. It is still necessary writing

“Table 1”or “Figure 1” even when there is only one table or one figure. The artwork should be prepared at the actual size that

they are to appear (single-column width is 8.0 cm; double-column width is (10–17) cm).

70


The data plot should be presented in its original Excel, GraphPad Prism or Origin figures, and chemical structures can be

prepared with ChemDraw.

A title is required on top of the table. The tables should be placed at the left side of the page. Limit the use of punctuations in

tables, align the numbers and texts neatly, and footnotes are indicated by superscript Roman letters a, b, c, etc.

4.7.2.7. NMR data

NMR data may be presented in either tables or in the text. Tables are preferred for complex NMR assignments and for series

of compounds with full assignments. Full assignments are encouraged using 2D NMR techniques, especially for large, complex

structures. The preferred order is: mp; [α]D; Rf values; spectral data (UV, IR); 1H NMR data; 13C NMR data; MS data. The

following is the preferred format: 1H NMR (500 MHz, CDCl3) δ: 7.02 (d, 1H, J 8.7 Hz, NHCO), 5.93 (m, 2H, CH2CH3)… 13C NMR (75 MHz, DMSO-d6)

δ: 158.4 (NHCO), 56.3 (CH2CH3)… HRMS calcd. for C15H20O3SNa (M+Na)+: 303.1025; found 303.1028…

4.7.3. Results and discussion

This section should include the newly obtained experimental results, conclusions, and limitations of the experiments. Especially

these experimental conditions that cannot be controlled easily should be pointed out. The discussion should be in the context of previous

findings and related with the objective, results, and conclusions of the experiments. Avoid repeating the results and do not review the

literatures in this part. Speculative deductions and conclusions without supporting data and evidence are not allowed.

4.8. Acknowledgments

This section is optional. Sources of financial support may be recognized here or in a footnote on the title page. Persons, who

made contributions to the research but not on the author list, could be listed here.

4.9. References

The references are cited numerically in the order of appearance in the main text. References are literature reports that have been

published. Papers that have been accepted for publication are marked by “In press”. Authors are expected to check the original source

for accuracy. Literature references are listed at the end of the main text and numbered. All references are written in Englis h.

References should be given in the following forms:

Periodicals: The listed reference consists of a serial number, names of all author (s), names of the Journal (Journal titles

should be abbreviated according to American Chemical Society guidelines), year of publication, volume (No.), and pages.

[1] Elvelin, L.; Jonsson, L. Mass Efficiency of Alkene Syntheses with Tri- and Tetrasubstituted Double Bonds. Curr. Ther.

Res. 1994, 55, 736–746.

Books: The listed book consists of a serial number, names of the author (s), names of the books, volume, year of publication,

publisher location, and publisher name.

[2] Cong, P.Z.; Su, K.M. Analytic Chemistry Handbook. Vol 9. 2nd ed. Beijing: Chemical Industry Press. 2000, 726–727.

Chapters of a book: Literature references should include author (s), chapter title (if applicable), editor (s), book title,

edition/volume, publisher location, publisher name, date and pages.

[3] Thomson, R.; von Itzstein, M. N-Acetylneuraminic acid derivatives and mimetics as anti-influenza agents, in Carbohydrate-based

drug Discovery (Wong, C, H. Ed.), Wiley-VCH, Weinheim, 2003, xxx–xxx.

Patent: The patent reference consists of a serial number, patent inventor, patent number, patent country, the year of application.

[4] Ledrut, H.U.S. Patent 2551982, 1951; Chem. Abstr., 1952, 51, 7128i.

Theses: The text citation consists of a serial number, author (s), degrees, colleges (institutions), and year.

[5] Wang, X.X. Ph.D. thesis, Peking University. 2005.

Resources on line: The citation consists of a serial number, names of the author (s), names of the journals (databases), year,

volume (No.), and pages.

[6] Entrena, A.; Campos, J.M.; Gallo, M.A.; Espinosa, A. Arkivoc. 2005, VI, 88–108. This article can be found online at

http://www.arkat-usa.org/ark/journal/2005/I06_Juaristi/1383/EJ-1383C.asp.

5. Corrections

If errors of consequence are found in the published paper, a correction of the error should be sent by the author to the Editor-in-Chief

for publication in the journal’s Errata Section.

6. Conflicts of interest

Authors should indicate relevant conflicts of interest in the cover letter, including specific financial interests relevant to the subject

of their manuscript, employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations,

etc. Authors without relevant financial interests in the manuscript should state no such interest.

71


《中国药学》(英文版) 投稿须知

1. 范围

《中国药学》(英文版)为中国科协主管, 中国药学会主办, 北京大学药学院承办的英文药学综合性期刊, 现为月刊。

本刊主要报道药学领域各学科进展及科研成果, 旨在促进学术交流。本刊登载药学研究各学科, 包括药物化学、生药学、

天然产物、药物分析、药剂学、生物制剂学、药理学、药物代谢与处置、药物基因组学以及临床药学等方面, 同时报道

我国创新药物研究的政策、研究方向与动态、研究成果等。本刊在国内外公开发行, 已被美国《化学文摘》(CA), 美国

《乌利希国际期刊指南》(UIPD), 波兰《哥白尼索引》(IC), 英国《国际农业与生物科学研究中心》(CABI), 荷兰《文摘与

引文数据库》(SCOPUS), 日本《科学技术振兴集团(中国)数据库》(JSTChina), 瑞典DOAJ, 美国EBSCO, 中国科技核心期刊

(中国科技论文统计源期刊), 《中国科学引文数据库》(CSCD), 《中国期刊全文专题数据库》(CNKI)等收录, 并加入国际

CrossRef 组织, 为期刊每一篇论文注册DOI (Digital Object Identifier)号, 实现了文献的跨平台链接。2013–2015年获得“中国

科技期刊国际影响力提升计划”项目资助。2012、2014、2015年被评为“中国国际影响力优秀学术期刊”。

2. 稿件类型

刊登的稿件包括综述与进展、研究论文、简讯、学术动态等栏目。稿件不得包含出版过、已投送或近期计划投送别

处的内容。引用出版物上的图、表, 必须得到版权所有者的书面认可。来稿要求论点明确, 数据可靠, 结构严密, 层次分明,

文字精炼。

研究论文报道具有原始性和创新性的研究成果。

研究简讯报道具有原始性和创新性的阶段性研究成果。

学术动态报道药学各领域的发展方向、学术会议及著名学者观点等。

综述与进展对当前药学各领域的研究热点和前沿领域, 结合作者在该领域的工作进行的总结、评述。

3. 投稿要求

请作者按照国际医学期刊编辑委员会 (ICMJE) 制定的“生物医学期刊投稿的统一要求”进行投稿。

3.1. 投稿可通过本刊的网上投稿系统, 也可通过邮箱[email protected]进行。来稿请发电子版 (word格式保存), 请勿

一稿两投。来稿凡属基金项目、国家攻关项目, 请注明项目编号。来稿收取稿件处理费100元/篇。如若发表, 稿件版面

费为200元/页, 通过邮局汇至本刊。编辑部地址: 北京市海淀区学院路38号, 北京大学药学院《中国药学》(英文版)编辑

部, 邮编 100191。

3.2. 稿件应包括题目、作者及单位、英文摘要、关键词、正文、图、表格、致谢、参考文献、图解摘要等, 并标注

页码, 请附上中文文题、作者及单位地址、摘要、关键词 (中英文一致)。请登录本刊主页http://www.jcps.ac.cn查看样稿。

3.3. 来稿一经受理即发稿件回执, 作者收到回执请签订论文版权转让授权书。一般2个月左右通知作者稿件审理情况。

作者应及时按审阅专家提出的建议进行修改, 并将修改稿和对专家修改意见做答复说明返回编辑部。修改稿在1个月内

未发回编辑部, 作自行退稿处理。修改稿通过审定稿后将通知作者按要求提供最终修改稿, 以便送国外英文编辑审阅。

3.4. 文章发表前, 作者将收到校样和版面费通知。请作者仔细校对 (文责自负)。作者在收到校样2天内返回编辑部。

依照《著作权法》有关规定, 编辑部对来稿有删改权。

3.5. 来稿一经发表, 酌致作者稿酬, 并免费赠送当期期刊2本及论文的PDF电子版。本刊已编入《中国期刊全文专题

数据库》等数据库, 作者著作权使用费与本刊稿酬一次性付给, 如不同意可在投稿时声明。

72


4. 稿件撰写要求

4.1. 文章题目 (Title)

简明确切地反映论文的特定内容, 不宜过长。文题首字母大写, 除专有名词外其余小写, 齐左。

4.2. 作者及工作单位 (Authors and affiliation)

作者应是参与来稿专题研究工作的主要科技人员, 应对全文的内容负责, 并能回答文中的问题, 是论文的法定著作权

人和责任者。作者姓名间用逗号分开, 应注明责任作者 (*标出)。作者的汉语拼音名前姓后首字母大写(如: Limei Zhang,

Ping Wang)。外国作者的姓名写法遵从国际惯例。不同单位的作者在其右上角标出序号, 并在其相应单位前标出。

4.3. 脚注 (Footnotes)

包括基金项目 (注明项目编号), 责任作者的联系方式 (电话、传真和E-mail)。

4.4. 摘要 (Abstract)

摘要应简明扼要地用一段话叙述研究工作的目的、主要内容和结果, 不必做出评论和解释, 单独阅读摘要部分应对全

文内容有概括性了解, 其详尽程度可参照CA (Chemical Abstracts)的模式。摘要中尽可能不要用参考文献以及非标准化的

缩略语。

4.5. 图解摘要 (Graphical abstract)

作者应另页提供图解摘要, 用于本期目录编写, 以便于读者浏览。图解摘要应尽量用简明绘图方式表达提交论文的最

核心内容, 不要求全面覆盖文章内容。如果需要可添加少量文字叙述。若无绘图时只用文字表述亦可。格式上应包括文

章标题、全部作者姓名、绘图、必要的文字叙述 (少于50单词)。参见下例:

pp 88–99 Xiao-Xu-Ming decoction extract alleviates LPS-induced neuroinflammation associated with

down-regulating TLR4/MyD88 signaling pathway in vitro and in vivo

Xiao Cheng#, Huan Yang#, Yinglin Yang, Weihan Li, Man Liu, Yuehua Wang*, Guanhua Du*

Xiao-Xu-Ming decoction

Extract (XXM)

BV2 cells were pre-treated with XXM for 1 h and then exposed to 200 ng/mL LPS for another 24 h.

Balb/C mice were pre-treated with XXM for 7 days and then 5 mg/kg LPS-treated for 6 h.

XXM treatment

In vitro In vivo

TLR4/MyD88 signaling pathway

Neuroinflammation

(–)

(–)

73


pp 595–604 Synthetic studies toward resveratrol-based natural products polynapstilbenes A and B

Baiyang Jiang, Lingqi Qiu, Jinrong liu, Hanxuan Wang, Suwei Dong*

pp 716–727 Compound C17 inhibits the lung metastasis of breast cancer

Yaoyao Feng, Peili Jiao, Xiaoxue Yan, Zixi Xue, Ye Yao, Liang Yang, Daming Kong, Hong Su, Ling Yong,

Guoshu Chen*, Tianyan Zhou*

pp 749–759 Membrane binding of the pH sensitive antimicrobial peptide LAH4 studied by EPR spectroscopy

Yina Sheng, Shenlin Wang, Guoquan Liu*

(C17)

O

ON

N

NH2

HN

N

N

O

Fast

Fast

H+

OH–

Fast

Slow

PC

PG Very slow

O

Me

Me

O

OH

HO

HO

OOGlc

GlcPolynapstilbene

HO

Me

CH3

O

OH

OH

OMe

OMe

OH

MeO OMe

+

O

Me

Me

O

OH

MeO

HO

OH

MeO

2 steps

28%

74


4.6. 关键词 (Keywords)

关键词3~10个, 可从文题、摘要及正文中选取, 中英文一致, 应标注能反应论文特征内容、通用性较强的, 符合主题

词表的术语。应避免使用特别泛指的词语, 宜选自《医学主题词注释字顺表(MeSH)》和《中医中药主题词表》。关键词

首字母大写, 之间用逗号相隔。

4.7. 正文部分 (The body of paper)

研究论文一般分为前言、实验 (实验材料、方法)、结果与讨论三大部分。层次标题用阿拉伯数字连续编号, 尽量减

少层次。采用三级标题, 齐左。

4.7.1. 前言 (Introduction) 简明扼要地概述本论文的理论依据、研究思路、实验基础及国内外现状。明确提出本文

目的, 尤其是本文的创新性。标出主要参考文献。要特别尊重和总结前人在此领域的研究工作。

4.7.2. 实验部分 (Experimental or Materials and methods) 本期刊包括药学研究领域各方面, 实验部分格式难以统一。

建议包括通用方法、具体实验步骤、实验数据、数据处理和统计分析等部分。

4.7.2.1. 实验材料应说明主要材料来源、品种及规格。药名采用“国际非专利药名 (International Nonproprietary

Names, INN)”, 以《中国药品通用名称》(国家药典委员会办公室编, 化学工业出版社, 1997)为准。若为国家食品药品监督管

理局批准的新药, 则用批准的药名。少用代号, 尽量不用商品名。药名首次出现时应写出英文全称, 药名写在剂量前面。

4.7.2.2. 研究对象动植物、微生物应注明拉丁学名, 植物标本应说明鉴定人及存放地点。实验动物应标明清洁级和合

格证号, 报道的大鼠和小鼠至少应为清洁II级。实验动物或人的性别、年龄和实际测得的体重应该用均值±标准差

(mean±SD)及可信区间表示。当实验以人或动物为研究对象时, 作者应当声明。只有符合机构责任委员会的伦理 (道德)标

准或依照1975年制定的赫尔辛基宣言 (2000年修订), 才能进行人体实验。应该省略患者的姓名及医院号码。动物实验应该

遵循相关机构提供的维护与使用说明。

4.7.2.3. 实验方法尽量简洁明了, 数据报道注意有效数字位数和精度。凡文献已有记述的方法, 一般可引文献。对新

的或有实质性改进的方法要写明改进处。如果是自己创新的方法, 则宜详述, 以便他人重复。理论计算中采用的计算程

序、来源及计算机型号、语言应予以注明。

4.7.2.4. 计量单位及符号计量单位一律采用以国际单位制为基础的“中华人民共和国法定计量单位”(简称“法定

单位”)。请参阅《量和单位》(北京: 中国标准出版社)。

4.7.2.5. 国际代号与缩写文中尽可能采用国际代号与缩写。如: s (秒), min (分钟), h (小时), d (天), t (时间), IU (国际

单位), P (概率), UV (紫外), i.v. (静脉注射), i.m. (肌内注射), i.p. (腹腔注射), s.c. (皮下注射), i.c.v. (脑室内注射), i.a. (动脉注

射), p.o. (口服), i.g. (灌胃), in vivo (体内), in vitro (体外)。如果不是常用缩略词, 应在第1次出现时给出定义。

4.7.2.6. 数字作为量词与序数词一律用阿拉伯数字, 数字符号按国家标准GB3102.11-93执行。单位符号前的数字最

好在0.1~1000, 必要时改用适当的词头符号, 如: M, m或以10n, 10–n表示。数字的增加可用倍数, 减少则用分数或百分数

表示。2–6%应写为2%–6%, 2–6×104应写为2×104–6×104 或 (2–6)×104, 2×3×4 mm 应写为2 mm×3 mm×4 mm。

4.7.2.7. 表和图图表要设计合理, 即使单看图表就能大体了解实验内容 (图注和表注应适当简述实验内容)。图表中

量和单位应是量的符号在前 (斜体), 单位符号在后, 如: t (h) (表示以h为法定单位的时间)。图表都应用阿拉伯数字依次编

号, 只有1个时, 仍用表1或图1表示。图表分单栏 (8 cm宽) 和双栏 ((10~17) cm宽)放置。

图若是数据图请用Excel, GraphPad Prism或Origin 原图 (或者是右键可以编辑的图), 化学结构式请用ChemDraw;

图片请提供单独的原始图片 (jpg格式), 像素至少300 dpi分辨率。

表格用三线表, 栏目项不应有空缺。卧表无论双页码或单页码, 表方位为顶左底右。表内尽量不用或少用标点符号,

数字对齐 (如“±”号对齐, 小数点对齐等)。表注依次用a, b, c等表示, 写在右上角。

4.7.2.8. 在药物化学和天然药物化学类研究论文中出现的已知化合物, 标出报道文献。对于未知的新化合物, 需要提

供该化合物的相关数据, 推荐顺序为: mp; [α]D; Rf; 光谱数据 (UV, IR); 1H NMR; 13C NMR; MS。按照以下的格式列出:

1H NMR (500 MHz, CDCl3) δ: 7.02 (d, 1H, J 8.7 Hz, NHCO), 5.93 (m, 2H, CH2CH3)… 13C NMR (75 MHz, DMSO-d6) δ: 158.4

(NHCO), 56.3 (CH2CH3) …HRMS calcd. for C15H20O3SNa (M+Na)+: 303.1025; found 303.1028…

75


4.7.3. 结果与讨论 (Results and discussion)

主要阐述本文的新发现及得出的结果和观点, 说明实验不足之处, 尤其是(试验)条件难以或未能控制之处。不要重

复已在前言结果中叙述过的内容, 讨论中应联系实验(试验)的目的与结论, 结果与其它结果。避免不成熟的论断或资料

不足得出的结论。

4.8. 致谢 (Acknowledgments)

注明基金项目来源, 对本文有贡献的其他人员, 如协助工作或提供资料、材料者, 可放在致谢项, 对文稿帮助审阅修

改者则不列入。

4.9. 参考文献 (References)

限作者阅读过的近期发表的主要原始文献, 内部资料勿引, 已被采用尚未刊出的稿件可引入, 不可引用非公开出版或

发表的文献, 不能引用其他文章中引用的但未经核对原文的文献。在引文处按引用文献出现的先后顺序用阿拉伯数字依次

编号。按照SCI收录要求, 所引参考文献全部用英文表示, 不能用中文、日文、俄文等。已被采用而尚未刊出的稿件可列

为参考文献, 但在期刊名后用括号注明“in press”。作者对所引文献的准确性和完整性负责。

参考文献著录格式:

期刊 [序号] 所有作者. 文献标题. 杂志名缩写斜体. [应按照Chemical Abstracts Service Source Index (CASSI) 的格式 (请

上网查阅www.cas.org/sent.html)] 年, 卷, 起页–止页.

[1] Elvelin, L.; Jonsson, L. Mass Efficiency of Alkene Syntheses with Tri- and Tetrasubstituted Double Bonds. Curr. Ther.

Res. 1994, 55, 736–746.

专著和论文集 [序号] 作者. 书名. 卷. 版本项(第1版不写). 出版地: 出版社(商). 出版年, 引文页码.

[2] Cong, P.Z.; Su, K.M. Analytic Chemistry Handbook. Vol 9. 2nd ed. Beijing: Chemical Industry Press. 2000, 726.

专著析出文献析出文献作者(编者或章节作者). 题名,书名(主编), 卷. 版次. 出版地: 出版社. 年, 起页–止页.

[3] Thomson, R.; von Itzstein, M. N-Acetylneuraminic acid derivatives and mimetics as anti-influenza agents, in Carbohydrate-

based drug Discovery (Wong, C, H. Ed.), Wiley-VCH, Weinheim, 2003, xxx–xxx.

专利 [序号]. 专利所有者. 专利国别专利号, 公告日期或公开日期. 获取和访问路径.

[4] Pfahl, M.; Lernhardt, W.; Fanjol, A. WO 9842340, 1998.

学位论文编号. 作者. 学位, 大学(或研究所等). 年.

[5] Wang, X.X. Ph. D. thesis, Peking University. 2005.

电子资源编号. 列出所有作者. 杂志名(数据库名), 年, 卷(期), 起页–止页.

[6] Entrena, A.; Campos, J.M.; Gallo, M.A.; Espinosa, A. Arkivoc. 2005, VI, 88–108. This article can be found online at

http://www.arkat-usa.org/ark/ journal/2005/I06_Juaristi/1383/EJ-1383C.asp.

5. 关于更正、撤销声明

如发现已经发表的文章有错误, 应由作者向期刊主编提出。主编根据实际问题类型, 决定发表更正或者撤销声明。

6. 利益冲突声明

作者投稿时应该声明是否有和稿件相关的利益冲突, 如学术纷争和作者知情、资金、个人经济利益、工作等相关的

冲突。

2020年1月

Information for Authors drugs, pharmacology, pharmacokinetics, pharmacodynamics and drug metabolism,...

Documents

Transcript of Information for Authors drugs, pharmacology, pharmacokinetics, pharmacodynamics and drug metabolism,...